Pyridostigmine Used as a Nerve Agent Pretreatment Under Wartime Conditions
JAMA 266:693-695, Keeler,J.R.,et al, 1991
Management of Injuries Due to Chemical Weapons
BMJ 302:129-130, Murray,V.S.G.&Volans,G.N., 1991
Tacrine in Alzheimer's Disease
Lancet 337:989-992, Eagger,S.A.,et al, 1991
Tacrine (tetrahydroaminoacridine; THA) and Lecithin in Senile Dememtia of the Alzheimer Type:A Multicentre Trial
BMJ 300:495-499, Chatellier,G.,et al, 1990
Tetrahydroaminoacridine-Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease
NEJM 322:1272-1276, Gauthier,S.,et al, 1990
Tetrahydroaminoacridine (THA) in Alzheimer's Disease, Not Ready for Routine Use
BMJ 298:845-846, Graham,T.R.&Lewis,C.T., 1989
Long-Term Administration of Oral Physostigmine in Alzheimer's Disease
Neurol 38:1837-1841, Stern,Y.,et al, 1988
Physostigmine Improves ECT-Induced Memory Disturbances
Neurol 37:871-875, Levin,Y.,et al, 1987
Effects of Oral Physostigmine in Alzheimer's Disease
Ann Neurol 22:306-310, Stern,Y.,et al, 1987
Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
NEJM 315:1241-1245, Summers,W.K.,et al, 1986
Positive Response to Edrophonium in Patients with Neurotoxic Envenoming by Cobras (NAJA NAJA PHILIPPINENIS)
NEJM 315:1444-1448, Watt,G.,et al, 1986
Drug-Induced Seizures:A 10-Year Experience
Neurol 34:1582-1586, Messing,R.O.,et al, 1984
Memory Enhancement with Oral Physostigmine in Alzheimer's Disease
NEJM 308:720-721, Thal,L.J.,et al, 1983
Oral Physostigmine & Lecithin Improve Memory in Alzheimer Disease
Ann Neurol 13:491-496, Thal,L.J.,et al, 1983
Memory Decline in the Aged:Treatment with Lecithin & Physostigmine
Neurol 32:944-950, Drachman,D.A.,et al, 1982
Double-blind, Triple-crossover Trial of Low Doses of Oral Physostigmine in Inherited Ataxias
Neurol 31:288-292, Kark,R.A.P.,et al, 1981
Plasma Pyridostigmine Levels in Myasthenia Gravis
Neurol 31:145-150, White,M.C.,et al, 1981
Amitriptyline-induced Ophthalmoplegia
Neurol 31:1188-1190, Spector,R.H.,et al, 1981
Physostigmine In Gilles De La Tourettes Syndrome
NEJM 302:298, Stahl,S.M.,et al, 1980
Memory & Cognitive Function in the Elderly, A Preliminary Trial of Physostigmine
Arch Neurol 37:674-675, Drachman,D.A.,et al, 1980
Controversies About the Treatment of Myasthenia Gravis
JNNP 43:644-659, Rowland,L.P., 1980
Anticholinergic Toxicity
NEJM 300:1278, Caine,E.D., 1979
Physostigmine in Reye Syndrome
Ann Neurol 5:105, Pettegrew,J.W.,et al, 1979
Effects of Physostigmine & Lecithin on Memory in Alzheimer Disease
Ann Neurol 6:219-221, Peters,B.H.,et al, 1979
Enhancement Of Memory By Physostigmine
NEJM 301:946, Davis,K.L.,et al, 1979
Meige Disease:Striatal Dopaminergic Preponderance
Neurol 29:1126-1130, Tolosa,E.S.,et al, 1979
Amantadine Intoxication Reversed by Physostigmine
NEJM 298:516, Casey,D.E., 1978
Malabsorption of Pyridostigmine in Patients with Masthenia Gravis
Neurol 27:299, Cohan,S.L.,et al, 1977
Total Gaze Paresis in Amitriptyline Overdose
Neurol 27:695, Miadinich,E.K.,et al, 1977
Physostigmine in Familial Ataxias
Neurol 27:70, Kark,R.A.,et al, 1977
Drug Therapy of Tardive Dyskinesia
NEJM 296:257, Kobayashi,R.M., 1977
Pheniramine Aminosalicylate Overdosage:Reversal of Delirium & Choreiform Movements with Tacrine Treatment
Arch Neurol 34:313, Mendelson,G.,et al, 1977
Polymyalgia Rheumatica
NEJM 394:1097-1109, Dejaco,C.,et al, 2026
Asundexian for Secondary Stroke Prevention
NEJM 394:1467-1479, 1540, Sharm,M.,et al, 2026
A 28-Year-Old Man with Seizures and Thalamic Lesions
Neurol 106:e218065, Santos-Rojo,A.B.,et al, 2026
Safety and Outcomes of Dibigatran Reversal with Idarucizumab Before IV Thrombolysis in Patients with Acute Ischemic Stroke
Neurol 106:e218012, Saflund,M.,et al, 2026
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
NEJM 392:2309-2320, Nowak,R.J.,et al, 2025
Myasthenia Gravis - Redemption for B-Cell Depletion
NEJM 392:2382-2384, Wolfe,G.I. & Shelly,S., 2025
Efficacy and Safety of Selimetinib in Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas (KOMET): A Multcentre, International, Randomised Placebo-Controlled, Parallel, Double-Blind, Phase 3 Study
Lancet 405:2217-2230, Chen,A.P.,et al, 2025
Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025
Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025
Idiopathic Intracranial Hypertension
NEJM 393:1409-1414, Horton,J.C., 2025